Healthcare & Biotech — GLP-1, mRNA & Clinical Trial AI

Verdict

The GLP-1/mRNA/Clinical Trial AI thesis continues to build momentum across multiple vectors. The GLP-1 obesity TAM has been revised upward to ~$150B from ~$80B in 2023, driven by over 1 billion people living with obesity globally [E2488], while NVO is viewed as a classic compounder with catalysts from rising diabetes prevalence in developing markets like China and India [E1184]. Healthcare sector valuations remain compelling at a 17% discount to S&P 500 on forward P/E as of January 2026—wider only 12% of the time since 1995—with consensus expecting ~10% YoY earnings growth for 2026-2027 [E2357]. The AI integration angle is substantive: Morgan Stanley estimates AI could save $400B-$1.5T in healthcare and boost R&D productivity by 10-40% in approved medicines [E2489], while clinical trial AI companies like Noetik, Medidata, and Veeva are flagged as underexplored with demonstrable near-term revenues [E1116], and 64% of healthcare organizations already report positive ROI from generative AI [E4860].

What would falsify this thesis:

A major confirmed safety signal (cardiovascular, cancer, or thyroid risk) in large-scale GLP-1 post-marketing data, undermining the $150B TAM projection [E2488]
Government price controls or IRA-style negotiation frameworks applied to GLP-1s in major markets, materially compressing projected revenues—a live risk given populist healthcare reform pressure [E8969][E6914]
Clinical trial AI companies failing to demonstrate sustained revenue growth or pharma clients reverting to traditional CRO models, as hinted by Nvidia's pullout from Recursion Pharma [E1117], which would invalidate the 'underexplored' opportunity thesis [E1116]
Broader antitrust action against pharma concentration or significant Medicare expansion causing healthcare sector multiples to re-rate downward rather than close the valuation gap [E6914][E2357]

🟢 Supporting (12)

[E2058] DFTX has major trial report outs next several months. Will be huge move - just don't know which direction. Likes what he's been hearing and observing.

@Scott Leavitt · 2026-04-07 · slack

[E1185] Weight loss drugs have positive effects on health. People will want to look after themselves during massive societal changes. Believes Jesse is on the right track with NVO.

@Gary Winters · 2026-04-07 · slack

[E1184] NVO is a classic compounder that has been hit hard. Catalyst could be diabetes developing in China, India and other countries as they develop and eat more junk food.

@Jesse · 2026-04-07 · slack

[E1116] Looking at AI's role in biotech - DLA report says clinical trial AI companies (Noetik, Medidata, Veeva, Flatiron, TriNetX) are underexplored. Larger economic prize than discovery AI, demonstrable near-term revenues, underrepresented in AI pharma investment narrative.

@Will B · 2026-04-07 · slack

[E3462] World models transform drug discovery via end-to-end simulation of biological systems. AlphaFold cracked protein folding; world models take it further to simulate protein docking, drug molecule behavior, compound movement through virtual body. DeepMind opening first autonomous science lab — will synthesize and test hundreds of materials daily with AI/robots handling experiments and data analysis.

@Raoul Pal (Global Macro Investor) · 2026-02-09 · r2

[E2489] AI could save $400B-1.5T in healthcare, representing 17-53% of required savings to keep healthcare spend at ~20% of GDP. AI-boosted R&D productivity could drive 10-40% increase in approved medicines. Hospital AI implementation could generate $300-900B savings (10-20% of system costs).

@Morgan Stanley Research (Stephen Byrd, Michelle Weaver, et al.) · 2026-01-26 · r2

[E2488] Peak obesity TAM now projected at ~$150B ($80B US/$70B ex-US), up from ~$105B in April 2024 and ~$80B in 2023. Over 1 billion people living with obesity worldwide, 54% of adults expected overweight/obese by 2035. GLP-1 class enabling 15-25% body weight loss through reduced appetite.

@Morgan Stanley Research (Stephen Byrd, Michelle Weaver, et al.) · 2026-01-26 · r2

[E2357] ISG recommends overweight US and European healthcare stocks. US healthcare sector experienced most significant underperformance vs S&P 500 in 30+ years through September 2025. Trading at 17% discount to S&P 500 on forward P/E — wider only 12% of time since 1995. Consensus expects ~10% YoY earnings growth for 2026-2027. Target low-double-digit returns.

@Goldman Sachs Investment Strategy Group · 2026-01-26 · r2

[E5008] AI drug discovery and biotech integration; lifespan extension goal over next 20-50 years; pharma relative performance best month in 30 years; XBI outperforming NDX; VLM critical for medical imaging and diagnostics; Anthropic hiring life scientists.

@Jordi Visser · 2025-11-30 · transcript

[E4860] Healthcare poised for massive AI-driven transformation. Sector positioned for double-digit growth while remaining at below-market multiples. McKinsey: 64% of healthcare organizations already quantifying positive ROI from generative AI. Healthcare represents safer positioning than Mag 7 given affordability pressures and demographic tailwinds.

@Jordi Visser · 2025-08-17 · transcript

[E5187] Longevity and AI-driven drug discovery creating new healthcare paradigm. AI agents discovering drugs independently; longevity becomes massive bullish macro theme. Healthcare spending reduction possible through prevention/longevity.

@Jordi Visser · 2025-07-06 · transcript

[E4877] Healthcare sector positioned as structural beneficiary of affordability pressures. McKinsey data shows 64% of healthcare orgs quantifying positive ROI from generative AI. Sector growing regardless of macro cycle while trading below market multiples—relative safety in rotation scenario.

@Jordi Visser · 2025-03-30 · transcript

🔴 Challenging (0)

No challenging evidence yet.

💬 Commentary (8)

[E1186] Citrini's 2026 themes include Biotherapeutics with 'Fat Redistribution' targeting GLP-1 weight-loss drug theme and aesthetic treatments.

@thibault · 2026-04-07 · slack

[E1117] Used to like RXRX (Recursion Pharma) which runs AI clinical drug trials to narrow down candidates. It used to range between 5 and 15 nicely for options plays, but Nvidia pulled out. Got long dated options position but not going to carry on - not convinced it'll keep bouncing the range.

@Stuart Hardy · 2026-04-07 · slack

[E4269] Biotech and biomanufacturing are explicitly listed as priority sectors in the 15th FYP, with high-end medical devices also included. Biotech is identified as one of five sectors where disruption risk to DM incumbents is highest. Healthcare targets include raising licensed doctors to 3.7 per 1,000 people by 2030 (from 3.1) and licensed nurses to 5.1 (from 4.3).

@Rory Green / Sadeem Al Gaaod (TS Lombard) · 2026-03-20 · r2

[E3691] BCA maintains a structural overweight on healthcare versus market since April 2011 (+3.4% cumulative), and a Healthcare/T-Bond 40:60 combination since March 2014 (+47.9%). Also holds long US Biotech vs Tech (-22.4% since Feb 2022). Healthcare remains a core structural allocation despite recent underperformance.

@Dhaval Joshi (BCA Research) · 2026-02-13 · r2

[E3248] Energy Fuels is advancing a rare earth elements strategy alongside uranium, positioning as a diversified critical minerals platform. The Vara Mada heavy mineral sands Feasibility Study shows after-tax pre-FID NPV10% of $1.4 billion, with Phase 2 REE White Mesa mill expansion at NPV7.5% of $1.2 billion. Pending acquisition of Australian Strategic Materials for ~$299 million enhances vertical integration and REE capability outside China.

@Mike Kozak, Nicholas Lobo (Cantor Fitzgerald) · 2026-02-05 · r2

[E6914] Pharma companies are identified among key monopolistic sectors where concentration harms innovation and extracts wealth from consumers. While big pharma claims to drive significant innovation, the counter-argument is that concentrated industries spend less on R&D relative to size and tend to acquire and shelve technologies rather than develop them. This creates antitrust risk for the sector.

@Jonathan Tepper with Denise Hearn · 2025-12-06 · ka

[E8969] Gromen flags political risk from a potential Bernie Sanders presidential victory that could reshape the healthcare sector and broader market dynamics. UnitedHealth specifically named as an entity facing political risk in this scenario, as of February 2020.

@Luke Gromen · 2025-12-06 · ka

[E8331] Munger states American medical system costs are 'totally out of control' with no clear solution, noting Singapore achieves comparable outcomes at roughly 20% of US healthcare costs. This highlights systemic inefficiency in US healthcare spending without identifying specific investment implications.

@Charlie Munger · 2025-12-06 · ka